boston
life
sciences
said
tuesday
completed
patient
enrollment
phase
iii
trial
therafectin
company
oral
drug
treatment
rheumatoid
arthritis.the
company
said
required
patients
enrolled
double
blind
placebo
controlled
trial
based
20
week
duration
study
results
expected
available
second
half
1997
